Bryan Goldman

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

Robert F. Kushner, Salvatore Calanna, Melanie J. Davies et al. · Obesity · 2020 · 275 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Sean Wharton, Salvatore Calanna, Melanie J. Davies et al. · Diabetes Obesity and Metabolism · 2021 · 162 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Johannes F.E. Mann, Vivian Fonseca, Ofri Mosenzon et al. · Circulation · 2018 · 145 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

Steven P. Marso, Florian M.M. Baeres, Stephen C. Bain et al. · Journal of the American College of Cardiology · 2020 · 111 citations

Medicine, Endocrinology, Pharmacology +13

Recombinant long‐acting glyco<scp>PEG</scp>ylated factor <scp>IX</scp> (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials

Claude Négrier, Guy Young, Faraizah Abdul Karim et al. · Haemophilia · 2016 · 29 citations

Medicine, Hematology, Pharmacotherapy +17